Treating dementia by blood brain barrier opening to increase glymphatic clearance - From mechanisms to therapeutic applications
Akronym
OPEN_2
Bidragets beskrivning
Alzheimer's disease (AD) currently complicates the lives of 50 million people with deterioration of mental skills and personality. Today AD costs 1 trillion € annually and by 2030 the cost will double. In OPEN-consortium we have detected failures in a brain clearance mechanism that lead to AD. Based on our findings, we have further developed novel tools for detecting the failing brain clearance along with new ways to boost the brain clearance, such that the AD development might be slowed down or even prevented. In the continued plans are that we will further increase the efficiency of the treatment options and expand our research to see how efficient our tools are in detecting and monitoring AD pathology in humans. We aim to develop novel multi-level treatment strategy that incorporates a spectrum of options extending from easy to use non-invasive therapies into more invasive treatments for advanced diseases states that can be tailored to suite patient treatment at individual level.
Visa merStartår
2021
Slutår
2022
Beviljade finansiering
Rollen i Finlands Akademis konsortium
Ledare
Finansiär
Finlands Akademi
Typ av finansiering
Akademiprogram
Övriga uppgifter
Finansieringsbeslutets nummer
335720
Vetenskapsområden
Biokemi, cell- och molekylärbiologi
Forskningsområden
Solu- ja molekyylibiologia
Identifierade teman
brain, neuroscience